Free Trial
Your confirmation email is on its way. Please check your inbox for further instructions.

STERIS (STE) Stock Price, News & Analysis

$218.54
-1.00 (-0.46%)
(As of 07/1/2024 ET)
Today's Range
$217.65
$222.00
50-Day Range
$201.49
$235.89
52-Week Range
$195.47
$254.00
Volume
843,177 shs
Average Volume
498,209 shs
Market Capitalization
$21.60 billion
P/E Ratio
57.21
Dividend Yield
0.95%
Price Target
$241.60

STERIS MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
10.6% Upside
$241.60 Price Target
Short Interest
Bearish
3.13% of Float Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
-2.00
Upright™ Environmental Score
News Sentiment
1.75mentions of STERIS in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$1.80 M Sold Last Quarter
Proj. Earnings Growth
8.87%
From $9.24 to $10.06 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.62 out of 5 stars

Medical Sector

74th out of 914 stocks

Surgical Appliances & Supplies Industry

4th out of 18 stocks

STE stock logo

About STERIS Stock (NYSE:STE)

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services. It also provides capital equipment installation, maintenance, upgradation, repair, and troubleshooting services; preventive maintenance programs and repair services; instrument and endoscope repair and maintenance services; and custom process improvement consulting and outsourced instrument sterile processing services. The Applied Sterilization Technologies segment provides contract sterilization and testing services for medical device and pharmaceutical manufacturers through a network of approximately 50 contract sterilization and laboratory facilities. The Life Sciences segment designs, manufactures and sells consumable products, such as formulated cleaning chemistries, barrier, sterility assurance products, steam and vaporized hydrogen peroxide sterilizers, and washer disinfectors. This segment also offers equipment installation, maintenance, upgradation, repair, and troubleshooting services; and preventive maintenance programs and repair services. The Dental segment provides hand and electric-powered dental instruments, infection control products, conscious sedation, personal protective equipment, and water quality products for dental suite. The company serves its products and services to hospitals, other healthcare providers, and pharmaceutical manufacturers. The company was founded in 1985 and is based in Dublin, Ireland.

STE Stock Price History

STE Stock News Headlines

1k a day while computer does all work?
What I discovered is now helping me take in more than 1k a day. It's like a "magic key" to passive income every month.
Q4 2024 STERIS plc Earnings Call
Piper Sandler Reaffirms Their Hold Rating on Steris (STE)
1k a day while computer does all work?
What I discovered is now helping me take in more than 1k a day. It's like a "magic key" to passive income every month.
STERIS Announces Dividend of $0.52 per share
Steris: Moving On, Losing Its Teeth
See More Headlines

Company Calendar

Last Earnings
5/08/2024
Ex-Dividend for 6/26 Dividend
6/12/2024
Dividend Payable
6/26/2024
Today
7/01/2024
Next Earnings (Estimated)
8/06/2024
Fiscal Year End
3/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical appliances & supplies
Sub-Industry
Health Care Equipment
CUSIP
85915210
Employees
18,179
Year Founded
1987

Price Target and Rating

Average Stock Price Target
$241.60
High Stock Price Target
$265.00
Low Stock Price Target
$215.00
Potential Upside/Downside
+10.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
6 Analysts

Profitability

Net Income
$378.24 million
Pretax Margin
13.68%

Debt

Sales & Book Value

Annual Sales
$5.14 billion
Cash Flow
$14.00 per share
Book Value
$63.91 per share

Miscellaneous

Free Float
97,726,000
Market Cap
$21.65 billion
Optionable
Optionable
Beta
0.83

Social Links

Should I Buy STERIS Stock? STE Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in STERIS plc:

  • STERIS plc has shown consistent revenue growth over the past few quarters, indicating a strong financial performance.
  • The company has a solid dividend yield, providing investors with a steady income stream. Dividend yield is a financial ratio that shows how much a company pays out in dividends each year relative to its stock price.
  • Recent acquisitions by STERIS plc have expanded its market reach and product offerings, potentially leading to increased profitability in the future.
  • Analysts have a positive outlook on STERIS plc's stock, with many recommending it as a buy or strong buy, which could attract more investors.
  • The current stock price of STERIS plc is trading at a reasonable valuation compared to its industry peers, presenting a potential value investment opportunity for investors.

Cons

Investors should be bearish about investing in STERIS plc for these reasons:

  • STERIS plc operates in a highly regulated industry, which could lead to increased compliance costs and potential legal risks.
  • The company's high dividend payout ratio may limit its ability to reinvest in growth opportunities or withstand economic downturns. Dividend payout ratio is the proportion of earnings paid out as dividends to shareholders.
  • Market competition in the healthcare sector where STERIS plc operates is intense, which could pressure margins and hinder future growth prospects.
  • Fluctuations in foreign exchange rates could impact STERIS plc's international operations and financial performance, adding currency risk to the investment.
  • Recent global economic uncertainties and geopolitical tensions may affect STERIS plc's business operations and financial results, leading to potential volatility in its stock price.
These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, June 4, 2024. Please send any questions or comments about these STERIS pros and cons to contact@marketbeat.com.

STE Stock Analysis - Frequently Asked Questions

Should I buy or sell STERIS stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for STERIS in the last twelve months. There are currently 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" STE shares.
View STE analyst ratings
or view top-rated stocks.

What is STERIS's stock price target for 2024?

6 brokerages have issued 1-year price objectives for STERIS's stock. Their STE share price targets range from $215.00 to $265.00. On average, they expect the company's stock price to reach $241.60 in the next year. This suggests a possible upside of 10.6% from the stock's current price.
View analysts price targets for STE
or view top-rated stocks among Wall Street analysts.

How have STE shares performed in 2024?

STERIS's stock was trading at $219.85 at the beginning of 2024. Since then, STE stock has decreased by 0.6% and is now trading at $218.54.
View the best growth stocks for 2024 here
.

When is STERIS's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 6th 2024.
View our STE earnings forecast
.

How were STERIS's earnings last quarter?

STERIS plc (NYSE:STE) announced its quarterly earnings data on Wednesday, May, 8th. The medical equipment provider reported $2.58 EPS for the quarter, beating analysts' consensus estimates of $2.41 by $0.17. The medical equipment provider earned $1.42 billion during the quarter, compared to analysts' expectations of $1.41 billion. STERIS had a net margin of 6.95% and a trailing twelve-month return on equity of 13.73%. The firm's revenue for the quarter was up 10.8% compared to the same quarter last year. During the same quarter last year, the company posted $2.30 earnings per share.
Read the conference call transcript
.

How often does STERIS pay dividends? What is the dividend yield for STERIS?

STERIS declared a quarterly dividend on Wednesday, May 1st. Shareholders of record on Wednesday, June 12th will be given a dividend of $0.52 per share on Wednesday, June 26th. This represents a $2.08 annualized dividend and a dividend yield of 0.95%. The ex-dividend date of this dividend is Wednesday, June 12th.
Read our dividend analysis for STE
.

Is STERIS a good dividend stock?

STERIS (NYSE:STE) pays an annual dividend of $2.08 per share and currently has a dividend yield of 0.95%. The company has been increasing its dividend for 19 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 54.45%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, STE will have a dividend payout ratio of 20.68% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for STE.

What guidance has STERIS issued on next quarter's earnings?

STERIS issued an update on its FY25 earnings guidance on Wednesday, May, 8th. The company provided earnings per share guidance of $9.05 to $9.25 for the period, compared to the consensus earnings per share estimate of $9.33. The company issued revenue guidance of +6.5-7.5% yr/yr or $5.473 billion to $5.524 billion, compared to the consensus revenue estimate of $5.67 billion.

What is Walter M. Rosebrough, Jr.'s approval rating as STERIS's CEO?

196 employees have rated STERIS Chief Executive Officer Walter M. Rosebrough, Jr. on Glassdoor.com. Walter M. Rosebrough, Jr. has an approval rating of 79% among the company's employees.

What other stocks do shareholders of STERIS own?

Based on aggregate information from My MarketBeat watchlists, some companies that other STERIS investors own include Johnson & Johnson (JNJ), Home Depot (HD), AT&T (T), Visa (V), AbbVie (ABBV), Abbott Laboratories (ABT), Pfizer (PFE), Gilead Sciences (GILD), Mastercard (MA) and Medtronic (MDT).

Who are STERIS's major shareholders?

STERIS's stock is owned by a variety of institutional and retail investors. Top institutional investors include Cullen Investment Group LTD. (0.01%). Insiders that own company stock include Cary L Majors, Cynthia L Feldmann, Jacqueline B Kosecoff, John Adam Zangerle, Karen L Burton, Michael J Tokich, Mohsen Sohi and Renato Tamaro.
View institutional ownership trends
.

How do I buy shares of STERIS?

Shares of STE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:STE) was last updated on 7/1/2024 by MarketBeat.com Staff

From Our Partners